NIOSHTIC-2 Publications Search

Selective induction of apoptosis through the FADD/caspase-8 pathway by a p53 c-terminal peptide in human pre-malignant and malignant cells.

Li Y; Mao Y; Rosal RV; Dinnen RD; Williams AC; Brandt-Rauf PW; Fine RL

Int J Cancer 2005 May; 115(1):55-64

https://doi.org/10.1002/ijc.20838

20028853

A p53 C-terminal peptide (aa 361-382, p53p), fused at its C-terminus to the minimal carrier peptide of antennapedia (17 aa, Ant; p53p-Ant), induced rapid apoptosis in human cancer cells, via activation of the Fas pathway. We examined p53p-Ant mechanism of action, toxicity in various human normal, non-malignant, pre-malignant and malignant cancer cells and investigated its biophysical characteristics. p53p-Ant selectively induced cell death in only pre-malignant or malignant cells in a p53-dependent manner and was not toxic to normal and non-malignant cells. p53p-Ant was more toxic to the mutant p53 than wild-type p53 phenotype in H1299 lung cancer cells stably expressing human temperature-sensitive p53 mutant 143Ala. Surface plasmon resonance (BIACORE) analysis demonstrated that this peptide had higher binding affinity to mutant p53 as compared to wild-type p53. p53p-Ant induced-cell death had the classical morphological characteristics of apoptosis and had no features of necrosis. The mechanism of cell death by p53p-Ant was through the FADD/caspase-8-dependent pathway without the involvement of the TRAIL pathway, Bcl-2 family and cell cycle changes. Blocking Fas with antibody did not alter the peptide's effect, suggesting that Fas itself did not interact with the peptide. Transfection with a dominant-negative FADD with a deleted N-terminus inhibited p53p-Ant-induced apoptosis. Its mechanism of action is related to the FADD-induced pathway without restoration of other p53 functions. p53p-Ant is a novel anticancer agent with unique selectivity for human cancer cells and could be useful as a prototype for the development of new anti-cancer agents.

Cancer; Humans; Toxins; Toxic-effects; Biophysics; Lung-cancer; Cell-damage; Pulmonary-system-disorders; Respiratory-system-disorders

Robert L. Fine, College of Physicians and Surgeons, Columbia University Medical Center, 650 West 168th Street, BB 20-05, New York, NY 10032

IJCNAW

20050501

Journal Article

rlf20@columbia.edu

Grant

2005

Grant-Number-R01-OH-007590

1

0020-7136

Research Tools and Approaches: Cancer Research Methods

International Journal of Cancer

NY

Columbia University Health Sciences